Clinical trial
Trial of the Efficacy and Safety of Pathogenetic Therapy of Multiple Sclerosis and Other Autoimmune Diseases Using Intrathecal Rituximab
NCT05078177 is registered in ClinicalTrials.gov with St. Petersburg State Pavlov Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Trial of the Efficacy and Safety of Pathogenetic Therapy of Multiple Sclerosis and Other Autoimmune Diseases Using Intrathecal Rituximab
- Lead sponsor
- St. Petersburg State Pavlov Medical University
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- December 21, 2020
- Completion date
- December 21, 2024
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.